Skip to main content
. 2004 Aug 15;18(16):1958–1963. doi: 10.1101/gad.1196104

Figure 4.

Figure 4.

RPA1 is required for FANCD2 monoubiquitination following MMC treatment. (A) Immunoblots demonstrate that attenuation of RPA1 with siRNA strongly inhibits FANCD2 monoubiquitination in HeLa cells following treatment with 0.5 μM MMC for 24 h. (B) RPA2 colocalizes with FANCD2 in DNA-damage foci following 24 h treatment of HeLa cells with 0.5 μM MMC. (C) The formation of FANCD2 foci at 24 h treatment with 0.5 μM MMC is decreased strongly in HeLa cells in which either ATR or RPA1 had been attenuated with siRNA. (D) Dot plots of BrdU incorporation and DNA content demonstrate that siRPA does not suppress normal DNA replication during S phase (box). (E) Transformed human lung fibroblasts (IMR90) in which RPA1 has been silenced with siRNA form radial chromosomes in response to 48 h treatment with 0.032 μM MMC.